Related Experiment Video
Updated: May 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Stent restenosis and thrombosis: etiology, treatment, and outcomes
F van Buuren1, J B Dahm, D Horskotte
1Department of Cardiology, Heart and Diabetes Center, North Rhine-Westphalia Ruhr University, Bochum, Germany. fvbuuren@hdz-nrw.de
Insights
Drug-eluting stents (DES) reduce restenosis and reintervention after coronary interventions. Newer biodegradable and polymer-free DES show promise for improved vessel function and reduced need for long-term antiplatelet therapy.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Drug-eluting stents (DES) significantly reduce restenosis and reintervention rates compared to bare metal stents (BMS) after percutaneous coronary intervention.
- Despite benefits, long-term safety concerns, particularly stent thrombosis, necessitate careful evaluation.
- Optimal stent implantation and antiplatelet therapy are crucial for successful outcomes.
Purpose of the Study:
- To review the etiology, treatment, and outcomes of in-stent restenosis.
- To provide an overview of new developments in stent technology, including biodegradable and polymer-free DES.
Main Methods:
- Review of randomized controlled trials comparing DES and BMS.
- Analysis of clinical presentations and management strategies for in-stent restenosis.
- Evaluation of emerging stent technologies and their potential benefits.
Main Results:
- DES consistently demonstrate significantly reduced reintervention rates compared to BMS.
- Newer DES with biodegradable polymers, novel coatings, and polymer-free designs show promising early results.
- Bioresorbable DES platforms offer potential for improved vessel function and reduced duration of dual antiplatelet therapy.
Conclusions:
- DES represent a significant advancement in reducing restenosis after coronary interventions.
- Emerging stent technologies, particularly bioresorbable DES, hold promise for enhanced patient outcomes and treatment paradigms.
- Continued research is essential to fully elucidate the long-term safety and efficacy of novel stent platforms.
Abstract:
The implementation of bare metal stents and later drug eluting stents (DES) proved to be an important step forward in reducing rates of restenosis after percutaneous coronary intervention. Despite all the benefits of DES, concerns have been raised over their long term safety as especially stent thrombosis sets patients at risk. In view of the overall low frequency of stent thrombosis, large sample sizes are needed to evaluate accurately treatment differences between stents. However, a consistent finding from randomized, controlled trials of DES versus bare metal stents is the significantly reduced reintervention rate associated with DES use. The clinical presentation of restenosis is recurrent angina or acute coronary syndrome. Optimal implantation of the stent in the vessel and adequate antiplatelet therapy are of utmost significance to provide best results. Intravascular imaging often helps to provide optimal delivery of the stent. Newer stents have now been developed. Especially DES with biogradable polymers, novel coatings of the stent, and polymer free DES have to be mentioned and early results seem to be promising. The perspective of bioresorbable DES platforms includes the additional benefits of improved recovery in vessel function and the potential for reducing the requirement for prolonged dual antiplatelet therapy. This article reviews the etiology, treatment options and outcome of in stent restenosis and gives an overview about the new developments in the field of stent technology.
Related Concept Videos
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management

